ESMO 2018 | PD-L1 and other biomarkers for renal cell carcinoma

Hans Hammers

Biomarkers drastically increase response rates to targeted therapies; here, Hans Hammers, MD, PhD, of the University of Texas Southwestern Medical Center, Texas, USA, discusses biomarkers for renal cell carcinoma, speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video